2001 News

December 1, 2001 New York, N.Y. - In lieu of its traditional holiday acknowledgements to clients and business partners, Kyowa Hakko USA and Kyowa Hakko Kogyo Co. are making contributions to two disaster relief organizations on their behalf. Combined contributions of over $200,000 have been made to the World Trade Center Fund and to the American Red Cross by the two companies. "In light of recent events and in keeping with America's undaunted spirit of unity and renewal, we believe this to be a more meaningful way to celebrate this season of joy, hope and sharing," stated Toshi Asada, P...

September 1, 2001 Soy Poised to Hit the Mainstream Source: Nutritional Outlook Grown all over the world and a staple in many Asian diets, the soybean is enjoying increasing popularity in the United States. After FDA announced in 1999 that diets low in saturated fats and cholesterol that include 25g of soy protein per day could lower the risk of heart disease, U.S. sales of soy products accelerated dramatically. Kyowa Hakko USA (New York City) manufactures CSPHP Kyowa SuperSoy, a soy peptide that reduces serum concentrations of total cholesterol and LDL cholesterol levels, according t...

August 27, 2001 Specialty Ingredient Focus: Soy Source: Chemical Market Reporter Soy and soy-derived products are important ingredients in the growth strategies of several chemical companies and agribusinesses that are targeting the dietary supplement, functional food and personal care markets. Kyowa Hakko launched a new soy peptide food ingredient for the functional food and dietary supplement market earlier this year. The new product, CSPHP Kyowa SuperSoy, binds enzymatic-decomposed lecithin to hydrolyzed isolated soy protein. Kyowa is manufacturing the soy ingredient at its facilit...

August 15, 2001 NEW YORK, N.Y. - Kyowa Hakko Kogyo Co., Ltd. will introduce its new serum cholesterol-reducing soy peptide, CSPHP SuperSoy, to the global nutrition community at the 17th International Congress of Nutrition 2001 in Vienna, Austria. The new product fortifies soy's acknowledged serum cholesterol-reducing properties by binding enzymatic-decomposed lecithin to hydrolyzed isolated soy protein. In clinical trials, patients taking as little as 3 grams of CSPHP Kyowa SuperSoy per day saw their high cholesterol levels return to normal. For supplement, nutraceutical, and food produ...

July 23, 2001 Source: Fortune Magazine Based on dramatic progress in the life sciences, Kyowa Hakko is developing a new generation of advanced drugs, including anti-cancer treatments, sold worldwide. The origins of Kyowa Hakko Kogyo Co., Ltd. go back to laboratories established in 1937 that aimed to produce aircraft fuel from sugar. Currently, one seventh of its sales come from its biochemicals division; now company president and CEO, Dr. Tadashi Hirata is excited about the potential of human genome research. A diverse company? Not really. From the word go, Kyowa Hakko has stuck to o...

June 25, 2001 Source: Chemical Market Reporter A manufacturing challenge in amino acids was solved earlier this year by Wacker-Chemie, Germany, which has developed a fermentation technology for making L-cysteine. Wacker Biochem Corp., the U.S. biotech venture of Wacker, partnered with Kyowa Hakko USA, a leading marketer and producer of amino acids, to market and sell Wacker-produced cysteine in the U.S. The fermentation technology is a significant breakthrough for manufacturing L-cysteine. Up to now, cysteine has mostly been extracted from raw materials of animal and human origins. It i...

June 1, 2001 CSPHP Kyowa SuperSoy is a newly developed soy peptide that significantly decreases serum concentrations of total cholesterol and LDL cholesterol. It was made by fortifying soy's widely known serum-cholesterol reducing property by binding enzymatic-decomposed lecithin to hydrolyzed isolated soy protein in the ration of 80/20 (wt/wt). The two components are considered to be bonded in a hydrophobic manner. Animal Testing: Cross-over tests, using male Wistar rats, indicated that SPHP [fractionated CSPHP] produced the effects of both reducing high cholesterol levels and suppressi...

May 21, 2001 Source: Chemical & Engineering News Japan has a rich tradition of developing materials through fermentation. Large companies such as Kyowa Hakko characterize fermentation as their core business. These companies have traditionally concentrated on food additives and multiclient products, rather than the advanced custom intermediates emphasized by Europe's biocatalysis experts, but a few of Japan's leading firms are now attempting to crack this market as well. For many decades, the Japanese have been impressed by the potential of fermentation processes to produce items othe...

May 1, 2001 NEW YORK, New York - Wacker Biochem Corporation and Kyowa Hakko USA have formed an alliance to market and sell Wacker-produced Cysteine in the United States. Cysteine, one of the twenty amino acids found in living organisms, is used extensively in the pharmaceutical, food and flavor, pet food, nutraceutical and cosmetic industries. The US market is estimated to be in the range of 700 MT per year. Wacker has developed a breakthrough fermentation technology for manufacturing Cysteine. Up to now Cysteine was extracted from ceratine, for instance, from human hair or from chicken f...

March 1, 2001 Kyowa Hakko Introduces CSPHP, Serum Cholesterol Reducing "KyowaSuperSoy" NEW YORK, New York - Kyowa Hakko announced the availability of a new soy peptide food ingredient, KyowaSuperSoy, that significantly reduces serum concentrations of total cholesterol and LDL cholesterol to healthy levels. The new product, CSPHP KyowaSuperSoy, fortifies soy's acknowledged serum-cholesterol reducing properties by binding enzymatic-decomposed lecithin to hydrolyzed isolated soy protein. In clinical trials, patients taking as little as 3 grams of CSPHP KyowaSuperSoy per day saw their high ...